<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944528</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00015617</org_study_id>
    <nct_id>NCT00944528</nct_id>
  </id_info>
  <brief_title>Single Dose Partial Breast Radiotherapy</brief_title>
  <acronym>RSU</acronym>
  <official_title>Single Dose Partial Breast Radiotherapy Using Extra-cranial Radiosurgery in Patients With Early Stage Breast Cancer - a Phase I Dose Escalation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine the maximum tolerated dose of a single-dose partial breast
      radiation given before lumpectomy using a radiosurgery technique. Lumpectomy will be
      performed within 3 weeks (+/- 1 week) of completing radiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the safety of partial breast radiosurgery as measured by the incidence
      of acute toxicity and wound healing complications in three dose cohorts.

      Patients will be enrolled in cohorts of 8 patients starting at dose level 1 (15 Gy). If 2 or
      more dose limiting toxicities (DLTs) are observed at dose level 1, the trial will be stopped
      for evaluation and consideration of revision. If at most one DLT is observed then escalation
      continues to the next dose level. The cohorts will escalate by 3Gy up to 21 Gy of
      irradiation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Actual">April 4, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>30 days</time_frame>
    <description>As measured by the incidence of acute toxicity and wound healing complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>3 yrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome</measure>
    <time_frame>3 yrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Images(MRI)</measure>
    <time_frame>Pre and post SRS radiosurgery</time_frame>
    <description>Pre and post-radiotherapy for exploratory analysis of radiation response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquire tissue</measure>
    <time_frame>Pre and post SRS radiosurgery</time_frame>
    <description>Pre and post-radiotherapy for exploratory analysis of radiation response</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Single dose radiosurgery: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 15 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose radiosurgery: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 18 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose radiosurgery: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 21 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiosurgery</intervention_name>
    <description>Single dose or radiation in 15Gy, 18Gy or 21Gy</description>
    <arm_group_label>Single dose radiosurgery: Dose Level 1</arm_group_label>
    <arm_group_label>Single dose radiosurgery: Dose Level 2</arm_group_label>
    <arm_group_label>Single dose radiosurgery: Dose Level 3</arm_group_label>
    <other_name>External beam radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with a biopsy proven diagnosis of low/intermediate grade ductal carcinoma in
             situ or invasive ductal (or other favorable histology) carcinoma of the breast

          -  Breast preservation candidates (no prior breast or nodal radiotherapy, no imaging
             evidence of multicentric or multifocal disease, no pregnant women, and no comorbid
             conditions precluding surgery)

          -  Clinical T1N0M0

          -  55 years of age or older

          -  Estrogen receptor (ER) positive,

          -  No evidence of lymphovascular space invasion on initial biopsy

          -  Not pregnant. If not post-menopausal must adhere to birth control measures

          -  White blood cell count &gt; 3000, Hemoglobin &gt; 9, platelets &gt;100000

          -  Must be eligible for MRI on initial evaluation and GFR at least 60 ml/min

        Exclusion Criteria:

          -  Neoadjuvant chemotherapy

          -  Breast implants

          -  Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus,
             rheumatoid arthritis, scleroderma)

          -  Patients unable to receive study treatment planning secondary to body habitus or
             inability to lie flat on the stomach at length

          -  HER-2/neu positive

          -  Positive serum pregnancy test
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Horton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Dept of Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nattinger AB, Hoffmann RG, Kneusel RT, Schapira MM. Relation between appropriateness of primary therapy for early-stage breast carcinoma and increased use of breast-conserving surgery. Lancet. 2000 Sep 30;356(9236):1148-53.</citation>
    <PMID>11030294</PMID>
  </reference>
  <reference>
    <citation>Hepel JT, Tokita M, MacAusland SG, Evans SB, Hiatt JR, Price LL, DiPetrillo T, Wazer DE. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1290-6. doi: 10.1016/j.ijrobp.2009.01.009. Epub 2009 Apr 22.</citation>
    <PMID>19395195</PMID>
  </reference>
  <reference>
    <citation>Luini A, Orecchia R, Gatti G, Intra M, Ciocca M, Galimberti V, Veronesi P, Santos GR, Gilardi D, Veronesi U. The pilot trial on intraoperative radiotherapy with electrons (ELIOT): update on the results. Breast Cancer Res Treat. 2005 Sep;93(1):55-9.</citation>
    <PMID>16184459</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer of Breast</keyword>
  <keyword>Cancer of the Breast</keyword>
  <keyword>Neoplasms, Breast</keyword>
  <keyword>Single dose radiation</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Preoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

